6.7M XNYS Volume
XNYS 17 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 225 | 11,690 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 188 | 3,013 | - | - | Deferred Share Units | |
| Robert J. Decker | VP Corporate Controller | Sale of securities on an exchange or to another person at price $ 165.88 per share. | 25 Feb 2025 | 6,999 | 21,001 (0%) | 0% | 165.9 | 1,160,994 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 6,999 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 25 Feb 2025 | 6,999 | 28,000 (0%) | 0% | 101.9 | 712,988 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 15 Feb 2025 | 385 | 15,542 (0%) | 0% | 156.2 | 60,118 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 15,927 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 2,698 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 13,513 | 13,513 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 219,020 | 219,020 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,632 | 5,632 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 91,277 | 91,277 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 2,127 | 2,127 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 34,476 | 34,476 | - | - | Employee Stock Options (Right to Buy) | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,903 | 1,903 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 30,841 | 30,841 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 8,357 | 8,357 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,031 | 1,031 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 25,538 | 25,538 | - | - | Employee Stock Options (Right to Buy) | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,576 | 1,576 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,189 | 3,189 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 51,688 | 51,688 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 49,878 | 49,878 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,077 | 3,077 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 27,951 | 27,951 | - | - | Employee Stock Options (Right to Buy) | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,725 | 1,725 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 2,806 | 0 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 14 Feb 2025 | 1,015 | 16,889 (0%) | 0% | 156.7 | 159,061 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 2,806 | 17,904 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 8,386 | 406,819 (0%) | 0% | 156.7 | 1,314,170 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 19,282 | 0 | - | - | Performance Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,682 | 7,364 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,053 | 0 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,470 | 3,469 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,470 | 392,498 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,053 | 396,041 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 1,510 | 390,988 (0%) | 0% | 155.3 | 234,443 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 2,198 | 393,843 (0%) | 0% | 156.7 | 344,449 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,682 | 397,525 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 1,602 | 395,923 (0%) | 0% | 156.1 | 250,152 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 19,282 | 415,205 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,316 | 20,661 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,779 | 1,779 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 507 | 1,272 (0%) | 0% | 155.3 | 78,717 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,014 | 5,286 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 1,144 | 4,142 (0%) | 0% | 156.7 | 179,276 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,971 | 6,113 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,316 | 0 | - | - | Performance Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,971 | 3,942 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,014 | 0 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,779 | 1,779 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 768 | 5,345 (0%) | 0% | 156.1 | 119,923 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 6,661 | 14,000 (0%) | 0% | 156.7 | 1,043,845 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 983 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,961 | 0 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 447 | 447 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 889 | 18,849 (0%) | 0% | 156.7 | 139,315 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,118 | 19,738 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 141 | 16,620 (0%) | 0% | 156.1 | 22,017 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 16,761 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 558 | 16,269 (0%) | 0% | 156.7 | 87,444 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,961 | 16,827 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 447 | 15,018 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 152 | 14,866 (0%) | 0% | 155.3 | 23,600 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,118 | 0 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,053 | 0 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,594 | 3,188 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,465 | 0 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,302 | 167,221 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 410 | 166,811 (0%) | 0% | 155.3 | 63,657 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,053 | 170,864 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 1,348 | 169,516 (0%) | 0% | 156.7 | 211,245 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,594 | 171,110 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 651 | 170,459 (0%) | 0% | 156.2 | 101,654 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,465 | 185,924 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 7,911 | 178,013 (0%) | 0% | 156.7 | 1,239,733 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,302 | 1,302 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 1,212 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 0 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 89,602 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 223 | 89,379 (0%) | 0% | 155.3 | 34,623 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 90,909 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 480 | 90,429 (0%) | 0% | 156.7 | 75,221 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 91,036 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 200 | 90,836 (0%) | 0% | 156.2 | 31,230 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 96,673 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 2,393 | 94,280 (0%) | 0% | 156.7 | 375,007 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 0 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 372 | 21,001 (0%) | 0% | 156.7 | 58,296 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,351 | 21,373 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 339 | 20,116 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 254 | 19,777 (0%) | 0% | 156.7 | 39,804 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 850 | 20,031 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 104 | 19,181 (0%) | 0% | 155.3 | 16,147 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 312 | 19,285 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 850 | 0 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 339 | 677 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,351 | 0 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 312 | 312 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 94 | 20,022 (0%) | 0% | 156.1 | 14,678 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,830 | 0 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 997 | 23,594 (0%) | 0% | 156.7 | 156,240 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 2,910 | 24,591 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 158 | 21,681 (0%) | 0% | 156.2 | 24,672 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 21,839 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 574 | 21,347 (0%) | 0% | 156.7 | 89,952 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,830 | 21,921 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 151 | 20,091 (0%) | 0% | 155.3 | 23,444 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 408 | 20,242 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 983 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 2,910 | 0 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 408 | 408 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 464 | 10,902 (0%) | 0% | 156.7 | 72,713 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 8,991 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 215 | 8,776 (0%) | 0% | 155.3 | 33,381 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 851 | 9,627 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 267 | 9,360 (0%) | 0% | 156.7 | 41,842 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 961 | 10,321 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 307 | 10,014 (0%) | 0% | 156.1 | 47,938 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,352 | 11,366 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 851 | 0 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 961 | 1,922 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,352 | 0 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,029 | 2,056 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,765 | 0 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 499 | 499 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 156.15 per share. | 13 Feb 2025 | 403 | 15,098 (0%) | 0% | 156.1 | 62,928 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,029 | 15,501 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 639 | 14,472 (0%) | 0% | 156.7 | 100,138 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,765 | 15,111 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 193 | 13,346 (0%) | 0% | 155.3 | 29,965 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 499 | 13,539 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,007 | 12,966 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 141 | 11,959 (0%) | 0% | 155.3 | 21,892 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 411 | 12,100 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,601 | 0 | - | - | Performance Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 419 | 837 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,007 | 0 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 411 | 410 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 457 | 14,119 (0%) | 0% | 156.7 | 71,616 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,601 | 14,576 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 120 | 12,975 (0%) | 0% | 156.2 | 18,738 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 419 | 13,095 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 290 | 12,676 (0%) | 0% | 156.7 | 45,446 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 19,282 | 19,282 | - | - | Performance Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 15,316 | 15,316 | - | - | Performance Share Units | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 3,118 | 3,118 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 15,465 | 15,465 | - | - | Performance Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 5,837 | 5,837 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,351 | 1,351 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 2,910 | 2,910 | - | - | Performance Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,352 | 1,352 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 2,806 | 2,806 | - | - | Performance Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,601 | 1,601 | - | - | Performance Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 126,369 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 126,369 | 489,671 (0%) | 0% | 100.1 | 12,644,482 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 100,643 | 389,028 (0%) | 0% | 153.1 | 15,410,456 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 153.89 per share. | 07 Feb 2025 | 13,015 | 0 (0%) | 0% | 153.9 | 2,002,878 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 13,015 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 13,015 | 13,015 (0%) | 0% | 100.1 | 1,302,281 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 58,504 | 213,355 (0%) | 0% | 100.1 | 5,853,910 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 47,436 | 165,919 (0%) | 0% | 153.1 | 7,263,400 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 58,504 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 32,762 | 115,027 (0%) | 0% | 100.1 | 3,278,166 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 26,076 | 88,951 (0%) | 0% | 153.1 | 3,992,757 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 32,762 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Eugene A. Woods | Director | 31 Dec 2024 | 100 | 250 (0%) | 0% | 145.5 | 14,553 | Common Stock | |
| Mark A. Weinberger | Director | Purchase of securities on an exchange or from another person at price $ 147.22 per share. | 12 Dec 2024 | 1,000 | 1,000 (0%) | 0% | 147.2 | 147,220 | Common Stock |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 208 | 2,804 | - | - | Deferred Share Units | |
| Hewson Marillyn A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 334 | 11,380 | - | - | Deferred Share Units | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 302 | 10,954 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 188 | 2,574 | - | - | Deferred Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 30 Aug 2024 | 5,635 | 24,608 (0%) | 0% | 100.1 | 563,838 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Sale of securities on an exchange or to another person at price $ 165.06 per share. | 30 Aug 2024 | 5,635 | 18,973 (0%) | 0% | 165.1 | 930,113 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 5,635 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 9,809 | 0 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.16 per share. | 08 Jul 2024 | 5,018 | 19,834 (0%) | 0% | 147.2 | 738,449 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 9,809 | 24,852 (0%) | 0% | 0 | Common Stock | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 314 | 10,573 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 211 | 2,368 | - | - | Deferred Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2024 | 68,835 | 0 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2024 | 68,835 | 68,835 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2024 | 55 | 68,835 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 53,510 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 11,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 22,561 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 14,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 50,510 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 25,561 (0%) | 0% | 0 | Common Stock | |
| Anne M. Mulcahy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 21,470 | - | - | Deferred Share Units | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 10,173 | - | - | Deferred Share Units | |
| Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 2,858 | - | - | Deferred Share Units | |
| Hubert Joly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 6,464 | - | - | Deferred Share Units | |
| Mary C. Beckerle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 13,643 | - | - | Deferred Share Units | |
| Darius E. Adamczyk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 3,712 | - | - | Deferred Share Units | |
| Mark B. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 17,867 | - | - | Deferred Share Units | |
| Jennifer A. Doudna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 8,081 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 2,139 | - | - | Deferred Share Units | |
| Y. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 5,093 | - | - | Deferred Share Units | |
| Mark A. Weinberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 9,129 | - | - | Deferred Share Units | |
| D. Scott Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 15,603 | - | - | Deferred Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Sale of securities on an exchange or to another person at price $ 162.16 per share. | 13 Mar 2024 | 8,891 | 15,043 (0%) | 0% | 162.2 | 1,441,765 | Common Stock |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 234 | 8,787 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 491 | 491 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 261 | 753 | - | - | Deferred Share Units | |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 29,275 | 29,275 | - | - | Employee Stock Options (Right to Buy) | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,475 | 1,475 | - | - | Restricted Share Units | |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,819 | 1,819 | - | - | Restricted Share Units | |
| Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,782 | 4,782 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 49,658 | 49,658 | - | - | Employee Stock Options (Right to Buy) | |
| Decker J. Robert | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 8,175 | 8,175 | - | - | Employee Stock Options (Right to Buy) | |
| J. Wolk Joseph | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 5,913 | 5,913 | - | - | Restricted Share Units | |
| Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 76,981 | 76,981 | - | - | Employee Stock Options (Right to Buy) | |
| J. Joseph Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 95,197 | 95,197 | - | - | Employee Stock Options (Right to Buy) | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 46,406 | 46,406 | - | - | Employee Stock Options (Right to Buy) | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 23,745 | 23,745 | - | - | Employee Stock Options (Right to Buy) | |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 40,551 | 40,551 | - | - | Employee Stock Options (Right to Buy) | |
| Duato Joaquin | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 177,816 | 177,816 | - | - | Employee Stock Options (Right to Buy) | |
| Hait William N. | EVP, Chief EI and Med Officer | 15 Feb 2024 | 2,155 | 2,155 | - | - | Restricted Share Units | ||
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,883 | 2,883 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 65,163 | 65,163 | - | - | Employee Stock Options (Right to Buy) | |
| C. John Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,048 | 4,048 | - | - | Restricted Share Units | |
| D. James Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 23,745 | 23,745 | - | - | Employee Stock Options (Right to Buy) | |
| J. Decker Robert | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,016 | 1,016 | - | - | Restricted Share Units | |
| N. Hait William | EVP, Chief EI and Med Officer | 15 Feb 2024 | 34,696 | 34,696 | - | - | Employee Stock Options (Right to Buy) | ||
| James Swanson D. | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,475 | 1,475 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,085 | 3,085 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 11,046 | 11,046 | - | - | Restricted Share Units | |
| Peter Fasolo M. | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,519 | 2,519 | - | - | Restricted Share Units | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 408 | 24,143 (0%) | 0% | 0 | Common Stock | |
| Robert Decker J. | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 86 | 18,973 (0%) | 0% | 157.8 | 13,575 | Common Stock |
| J. Joseph Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,780 | 69,663 (0%) | 0% | 0 | Common Stock | |
| Taubert L. Jennifer | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 666 | 154,851 (0%) | 0% | 157.8 | 105,128 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 250 | 13,040 (0%) | 0% | 157.9 | 39,463 | Common Stock |
| Forminard Elizabeth | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 236 | 8,340 (0%) | 0% | 157.9 | 37,253 | Common Stock |
| Wolk J. Joseph | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 773 | 68,890 (0%) | 0% | 157.8 | 122,018 | Common Stock |
| E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 408 | 816 | - | - | Restricted Share Units | |
| Peter Fasolo M. | Exec VP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 474 | 112,076 (0%) | 0% | 157.9 | 74,821 | Common Stock |
| N. Hait William | See Remarks | 13 Feb 2024 | 834 | 39,074 (0%) | 0% | 0 | Common Stock | ||
| Swanson James D. | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 447 | 14,765 (0%) | 0% | 0 | Common Stock | |
| D. Swanson James | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 447 | 894 | - | - | Restricted Share Units | |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 925 | 112,550 (0%) | 0% | 0 | Common Stock | |
| N. William Hait | See Remarks | 13 Feb 2024 | 834 | 1,666 | - | - | Restricted Share Units | ||
| James Swanson D. | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 195 | 14,570 (0%) | 0% | 157.9 | 30,781 | Common Stock |
| J. Robert Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 313 | 624 | - | - | Restricted Share Units | |
| Decker J. Robert | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 313 | 19,059 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 1,507 | 363,302 (0%) | 0% | 157.9 | 237,880 | Common Stock |
| William N. Hait | See Remarks | 13 Feb 2024 | 427 | 38,647 (0%) | 0% | 157.9 | 67,402 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 3,470 | 364,809 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 3,470 | 6,939 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 499 | 998 | - | - | Restricted Share Units | |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 333 | 82,265 (0%) | 0% | 157.8 | 52,564 | Common Stock |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 209 | 23,934 (0%) | 0% | 157.9 | 32,991 | Common Stock |
| Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 8,576 (0%) | 0% | 0 | Common Stock | |
| Joseph Wolk J. | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,780 | 3,558 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 499 | 13,290 (0%) | 0% | 0 | Common Stock | |
| Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,302 | 155,517 (0%) | 0% | 0 | Common Stock | |
| M. Peter Fasolo | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 925 | 1,848 | - | - | Restricted Share Units | |
| Taubert L. Jennifer | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,302 | 2,604 | - | - | Restricted Share Units | |
| Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 82,598 (0%) | 0% | 0 | Common Stock | |
| Duato Joaquin | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 5,267 | 377,239 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 4,701 | 0 | - | - | Performance Share Units | |
| N. William Hait | See Remarks | 12 Feb 2024 | 7,647 | 0 | - | - | Performance Share Units | ||
| Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,448 | 8,548 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,448 | 0 | - | - | Performance Share Units | |
| Robert Decker J. | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,637 | 0 | - | - | Performance Share Units | |
| Wolk J. Joseph | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 22,119 | 0 | - | - | Performance Share Units | |
| William Hait N. | See Remarks | 12 Feb 2024 | 1,285 | 42,316 (0%) | 0% | 0 | Common Stock | ||
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 31,351 | 0 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 13,403 | 154,215 (0%) | 0% | 157.4 | 2,109,632 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 790 | 25,871 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 15,900 | 361,339 (0%) | 0% | 157.4 | 2,502,660 | Common Stock |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 2,136 | 23,735 (0%) | 0% | 157.4 | 336,206 | Common Stock |
| Hait William N. | See Remarks | 12 Feb 2024 | 7,647 | 41,031 (0%) | 0% | 0 | Common Stock | ||
| M. Peter Fasolo | Exec VP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 7,019 | 111,625 (0%) | 0% | 157.4 | 1,104,791 | Common Stock |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,987 | 89,013 (0%) | 0% | 0 | Common Stock | |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 12,808 | 0 | - | - | Performance Share Units | |
| Hait William N. | See Remarks | 12 Feb 2024 | 4,076 | 38,240 (0%) | 0% | 157.4 | 641,562 | Common Stock | |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 7,066 | 81,947 (0%) | 0% | 157.4 | 1,112,188 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 22,433 | 163,849 (0%) | 0% | 0 | Common Stock | |
| D. Swanson James | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 4,671 | 15,228 (0%) | 0% | 0 | Common Stock | |
| J. Wolk Joseph | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 3,716 | 78,699 (0%) | 0% | 0 | Common Stock | |
| J. Joseph Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 10,816 | 67,883 (0%) | 0% | 157.4 | 1,702,438 | Common Stock |
| E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 11,826 | 87,026 (0%) | 0% | 0 | Common Stock | |
| Fasolo M. Peter | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,152 | 118,644 (0%) | 0% | 0 | Common Stock | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 4,701 | 25,081 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 4,911 | 0 | - | - | Performance Share Units | |
| Forminard Elizabeth | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 1,034 | 7,925 (0%) | 0% | 157.4 | 162,752 | Common Stock |
| Robert Decker J. | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 523 | 18,746 (0%) | 0% | 157.4 | 82,320 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 275 | 19,269 (0%) | 0% | 0 | Common Stock | |
| Swanson James D. | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 1,695 | 14,318 (0%) | 0% | 157.4 | 266,793 | Common Stock |
| Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 825 | 15,678 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 22,119 | 74,983 (0%) | 0% | 0 | Common Stock | |
| Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 411 | 8,959 (0%) | 0% | 0 | Common Stock | |
| L. Jennifer Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 3,769 | 167,618 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 2,887 | 12,791 (0%) | 0% | 157.4 | 454,414 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 4,911 | 14,853 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 31,351 | 371,972 (0%) | 0% | 0 | Common Stock | |
| D. James Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 785 | 16,013 (0%) | 0% | 0 | Common Stock | |
| Kathryn Wengel E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 11,826 | 0 | - | - | Performance Share Units | |
| L. Taubert Jennifer | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 22,433 | 0 | - | - | Performance Share Units | |
| Decker J. Robert | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,637 | 18,994 (0%) | 0% | 0 | Common Stock | |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 12,808 | 116,492 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 4,671 | 0 | - | - | Performance Share Units | |
| Duato Joaquin | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 130,969 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.76 per share. | 09 Feb 2024 | 27,333 | 75,200 (0%) | 0% | 156.8 | 4,284,721 | Common Stock |
| Duato Joaquin | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 09 Feb 2024 | 130,969 | 439,283 (0%) | 0% | 90.4 | 11,844,836 | Common Stock |
| Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 35,638 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Duato Joaquin | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.76 per share. | 09 Feb 2024 | 98,662 | 340,621 (0%) | 0% | 156.8 | 15,466,255 | Common Stock |
| E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 09 Feb 2024 | 35,638 | 102,533 (0%) | 0% | 90.4 | 3,223,101 | Common Stock |
| Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 979 | 0 | - | - | Restricted Share Units | |
| Taubert Jennifer L. | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 3,739 | 0 | - | - | Restricted Share Units | |
| J. Wolk Joseph | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 3,686 | 53,911 (0%) | 0% | 0 | Common Stock | |
| Schmid Timothy | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,001 | 9,942 (0%) | 0% | 156.3 | 156,486 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 3,739 | 143,329 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 5,225 | 310,583 (0%) | 0% | 0 | Common Stock | |
| E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,971 | 0 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,964 | 0 | - | - | Restricted Share Units | |
| Decker J. Robert | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 655 | 17,572 (0%) | 0% | 0 | Common Stock | |
| L. Taubert Jennifer | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,913 | 141,416 (0%) | 0% | 156.3 | 299,059 | Common Stock |
| Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,964 | 10,943 (0%) | 0% | 0 | Common Stock | |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 781 | 103,684 (0%) | 0% | 156.3 | 122,094 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 215 | 17,357 (0%) | 0% | 156.3 | 33,611 | Common Stock |
| Forminard Elizabeth | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 979 | 6,463 (0%) | 0% | 0 | Common Stock | |
| J. Decker Robert | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 655 | 0 | - | - | Restricted Share Units | |
| Joseph Wolk J. | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 3,686 | 0 | - | - | Restricted Share Units | |
| Hait William N. | See Remarks | 08 Feb 2024 | 1,113 | 33,384 (0%) | 0% | 156.3 | 173,995 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,880 | 21,083 (0%) | 0% | 0 | Common Stock | |
| N. William Hait | See Remarks | 08 Feb 2024 | 3,059 | 34,497 (0%) | 0% | 0 | Common Stock | ||
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 703 | 20,380 (0%) | 0% | 156.3 | 109,900 | Common Stock |
| D. James Swanson | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,868 | 11,111 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,880 | 0 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,971 | 67,904 (0%) | 0% | 0 | Common Stock | |
| D. James Swanson | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,868 | 0 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 156.27 per share. | 08 Feb 2024 | 59,397 | 141,416 (0%) | 0% | 156.3 | 9,281,969 | Common Stock |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 2,135 | 0 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 2,269 | 308,314 (0%) | 0% | 156.3 | 354,713 | Common Stock |
| Wolk J. Joseph | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,047 | 52,864 (0%) | 0% | 156.3 | 163,678 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 5,225 | 0 | - | - | Restricted Share Units | |
| L. Taubert Jennifer | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 08 Feb 2024 | 59,397 | 200,813 (0%) | 0% | 90.4 | 5,371,865 | Common Stock |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 2,135 | 104,465 (0%) | 0% | 0 | Common Stock | |
| Hait N. William | See Remarks | 08 Feb 2024 | 3,059 | 3,059 | - | - | Restricted Share Units | ||
| James Swanson D. | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 554 | 10,557 (0%) | 0% | 156.3 | 86,607 | Common Stock |
| Kathryn Wengel E. | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,009 | 66,895 (0%) | 0% | 156.3 | 157,737 | Common Stock |
| L. Taubert Jennifer | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 59,397 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 363 | 6,100 (0%) | 0% | 156.3 | 56,748 | Common Stock |
| A. Marillyn Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 227 | 8,489 | - | - | Deferred Share Units | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2023 | 228 | 8,200 | - | - | Deferred Share Units | |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Aug 2023 | 232 | 102,464 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Aug 2023 | 11,035 | 305,358 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Aug 2023 | 67 | 50,275 (0%) | 0% | 0 | Common Stock | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Aug 2023 | 2,787 | 52,037 (0%) | 0% | 0 | Common Stock | |
| William Hait | See Remarks | 23 Aug 2023 | 696 | 87,051 (0%) | 0% | 0 | Common Stock | ||
| William Hait | See Remarks | 26 Jul 2023 | 14,698 | 102,445 (0%) | 0% | 90.4 | 1,329,287 | Common Stock | |
| William Hait | See Remarks | 26 Jul 2023 | 14,698 | 0 | - | - | Employee Stock Options (Right to Buy) | ||
| William Hait | See Remarks | 26 Jul 2023 | 14,698 | 87,747 (0%) | 0% | 172 | 2,528,056 | Common Stock | |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Sale of securities on an exchange or to another person at price $ 170.32 per share. | 25 Jul 2023 | 20,000 | 102,696 (0%) | 0% | 170.3 | 3,406,498 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Sale of securities on an exchange or to another person at price $ 160.00 per share. | 12 Jun 2023 | 12,465 | 65,933 (0%) | 0% | 160 | 1,994,400 | Common Stock |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 230 | 7,912 | - | - | Deferred Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 May 2023 | 55 | 50,342 (0%) | 0% | 0 | Common Stock | |
| Anne M. Mulcahy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 19,493 | - | - | Deferred Share Units | |
| D. Scott Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 13,799 | - | - | Deferred Share Units | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 7,624 | - | - | Deferred Share Units | |
| Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,429 | 1,429 | - | - | Deferred Share Units | |
| Hubert Joly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 4,928 | - | - | Deferred Share Units | |
| Mary C. Beckerle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 11,896 | - | - | Deferred Share Units | |
| Darius Adamczyk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 2,258 | - | - | Deferred Share Units | |
| Mark B. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 15,996 | - | - | Deferred Share Units | |
| Jennifer A. Doudna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 6,498 | - | - | Deferred Share Units | |
| Nadja Y West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 3,598 | - | - | Deferred Share Units | |
| Mark A. Weinberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 1,193 | 7,515 | - | - | Deferred Share Units | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2023 | 233 | 6,430 | - | - | Deferred Share Units | |
| A. Eugene Washington | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2023 | 201 | 28,569 | - | - | Deferred Share Units | |
| James D. Swanson | See Remarks | Sale of securities on an exchange or to another person at price $ 154.76 per share. | 06 Mar 2023 | 1,061 | 9,215 (0%) | 0% | 154.8 | 164,199 | Common Stock |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 5,765 | 122,696 (0%) | 0% | 162.0 | 933,988 | Common Stock |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 2,773 | 2,773 | - | - | Restricted Share Units | |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 45,890 | 45,890 | - | - | Employee Stock Options (Right to Buy) | |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 12,468 | 128,461 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 13,599 | 316,393 (0%) | 0% | 162.0 | 2,203,174 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 31,319 | 329,992 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,409 | 10,409 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 172,250 | 172,250 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 8,578 | 50,397 (0%) | 0% | 162.0 | 1,389,722 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,693 | 58,975 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 88,334 | 88,334 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 5,338 | 5,338 | - | - | Restricted Share Units | |
| James D. Swanson | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 918 | 10,277 (0%) | 0% | 162.0 | 148,725 | Common Stock |
| James D. Swanson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 22,191 | 22,191 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,341 | 1,341 | - | - | Restricted Share Units | |
| James D. Swanson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 3,228 | 11,195 (0%) | 0% | 0 | Common Stock | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 17,994 | 61,982 (0%) | 0% | 0 | Common Stock | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 3,704 | 3,704 | - | - | Restricted Share Units | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 61,295 | 61,295 | - | - | Employee Stock Options (Right to Buy) | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 7,158 | 54,824 (0%) | 0% | 162.0 | 1,159,668 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 10,569 | 139,590 (0%) | 0% | 162.0 | 1,712,284 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 3,906 | 3,906 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 21,422 | 150,159 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 64,634 | 64,634 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 4,891 | 78,398 (0%) | 0% | 162.0 | 792,391 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,839 | 83,289 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 32,317 | 32,317 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,953 | 1,953 | - | - | Restricted Share Units | |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 56,555 | 56,555 | - | - | Employee Stock Options (Right to Buy) | |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 3,417 | 3,417 | - | - | Restricted Share Units | |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 13,710 | 72,345 (0%) | 0% | 0 | Common Stock | |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 6,430 | 65,915 (0%) | 0% | 162.0 | 1,041,724 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 7,756 | 7,756 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 937 | 937 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,451 | 17,314 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 397 | 16,917 (0%) | 0% | 162.0 | 64,318 | Common Stock |
| William Hait | See Remarks | 13 Feb 2023 | 4,586 | 87,747 (0%) | 0% | 162.0 | 742,978 | Common Stock | |
| William Hait | See Remarks | 13 Feb 2023 | 2,500 | 2,500 | - | - | Restricted Share Units | ||
| William Hait | See Remarks | 13 Feb 2023 | 9,640 | 92,333 (0%) | 0% | 0 | Common Stock | ||
| William Hait | See Remarks | 13 Feb 2023 | 41,366 | 41,366 | - | - | Employee Stock Options (Right to Buy) | ||
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 1,440 | 19,203 (0%) | 0% | 162.0 | 233,294 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 3,981 | 20,643 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,263 | 20,263 | - | - | Employee Stock Options (Right to Buy) | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,224 | 1,224 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 32,317 | 32,317 | - | - | Employee Stock Options (Right to Buy) | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,953 | 1,953 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 2,555 | 6,408 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 924 | 5,484 (0%) | 0% | 162.0 | 149,697 | Common Stock |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,078 | 116,754 (0%) | 0% | 0 | Common Stock | |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 761 | 115,993 (0%) | 0% | 162.1 | 123,343 | Common Stock |
| Peter M. Fasolo | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,078 | 0 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 5,220 | 0 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 5,220 | 300,940 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 2,267 | 298,673 (0%) | 0% | 162.1 | 367,435 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 979 | 38,282 (0%) | 0% | 162.1 | 158,676 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 3,449 | 0 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 3,449 | 39,261 (0%) | 0% | 0 | Common Stock | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,999 | 0 | - | - | Restricted Share Units | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,999 | 44,811 (0%) | 0% | 0 | Common Stock | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 823 | 43,988 (0%) | 0% | 162.1 | 133,392 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 1,289 | 128,737 (0%) | 0% | 162.1 | 208,921 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 3,570 | 130,026 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 3,570 | 0 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,807 | 0 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 667 | 72,450 (0%) | 0% | 162.1 | 108,107 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,807 | 73,117 (0%) | 0% | 0 | Common Stock | |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 826 | 58,635 (0%) | 0% | 162.1 | 133,878 | Common Stock |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,285 | 0 | - | - | Restricted Share Units | |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,285 | 59,461 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 581 | 0 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 191 | 15,863 (0%) | 0% | 162.1 | 30,957 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 581 | 16,054 (0%) | 0% | 0 | Common Stock | |
| William Hait | See Remarks | 10 Feb 2023 | 1,399 | 82,693 (0%) | 0% | 162.1 | 226,750 | Common Stock | |
| William Hait | See Remarks | 10 Feb 2023 | 3,856 | 84,092 (0%) | 0% | 0 | Common Stock | ||
| William Hait | See Remarks | 10 Feb 2023 | 3,856 | 0 | - | - | Restricted Share Units | ||
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,592 | 17,259 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 597 | 16,662 (0%) | 0% | 162.1 | 96,762 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,592 | 0 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 380 | 3,853 (0%) | 0% | 162.1 | 61,590 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,022 | 4,233 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,022 | 0 | - | - | Restricted Share Units | |
| Alex Gorsky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 547,692 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Alex Gorsky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 17 Jan 2023 | 547,692 | 1,133,193 (0%) | 0% | 72.5 | 39,729,578 | Common Stock |
| Alex Gorsky | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.43 per share. | 17 Jan 2023 | 366,610 | 766,583 (0%) | 0% | 173.4 | 63,581,172 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.43 per share. | 17 Jan 2023 | 98,795 | 295,720 (0%) | 0% | 173.4 | 17,134,017 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 148,538 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 17 Jan 2023 | 148,538 | 394,515 (0%) | 0% | 72.5 | 10,774,947 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Dec 2022 | 18 | 35,840 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2022 | 12,926 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2022 | 1,855 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 179.62 per share. | 13 Dec 2022 | 12,926 | 35,812 (0%) | 0% | 179.6 | 2,321,755 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 179.46 per share. | 13 Dec 2022 | 1,855 | 48,738 (0%) | 0% | 179.5 | 332,906 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 13 Dec 2022 | 1,855 | 50,593 (0%) | 0% | 72.5 | 134,562 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 13 Dec 2022 | 12,926 | 48,738 (0%) | 0% | 90.4 | 1,169,027 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Dec 2022 | 28 | 35,812 (0%) | 0% | 0 | Common Stock | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2022 | 240 | 6,152 | - | - | Deferred Share Units | |
| A. Eugene Washington | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2022 | 350 | 28,162 | - | - | Deferred Share Units | |
| Mark A. Weinberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2022 | 241 | 6,276 | - | - | Deferred Share Units | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 176.09 per share. | 30 Nov 2022 | 1,400 | 113,735 (0%) | 0% | 176.1 | 246,529 | Common Stock |
| Ashley McEvoy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2022 | 73,323 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Ashley McEvoy | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 175.46 per share. | 30 Nov 2022 | 71,923 | 41,812 (0%) | 0% | 175.5 | 12,619,272 | Common Stock |
| Ashley McEvoy | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 30 Nov 2022 | 73,323 | 115,135 (0%) | 0% | 72.5 | 5,318,850 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 176.78 per share. | 22 Nov 2022 | 76,923 | 126,456 (0%) | 0% | 176.8 | 13,598,402 | Common Stock |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 76,923 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 22 Nov 2022 | 76,923 | 203,379 (0%) | 0% | 72.5 | 5,579,994 | Common Stock |
| Robert J. Decker | Controller, CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2022 | 16,928 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | Controller, CAO | Sale of securities on an exchange or to another person at price $ 175.00 per share. | 18 Nov 2022 | 16,928 | 15,473 (0%) | 0% | 175 | 2,962,400 | Common Stock |
| Robert J. Decker | Controller, CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 18 Nov 2022 | 16,928 | 32,401 (0%) | 0% | 90.4 | 1,530,968 | Common Stock |
| Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 09 Nov 2022 | 16,410 | 87,720 (0%) | 0% | 72.5 | 1,190,381 | Common Stock |
| Kathryn E. Wengel | EVP, Chief GSC Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2022 | 16,410 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief GSC Officer | Sale of securities on an exchange or to another person at price $ 173.42 per share. | 09 Nov 2022 | 16,410 | 71,310 (0%) | 0% | 173.4 | 2,845,773 | Common Stock |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 7,010 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 10,033 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 07 Nov 2022 | 7,010 | 57,176 (0%) | 0% | 101.9 | 714,109 | Common Stock |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.67 per share. | 07 Nov 2022 | 10,033 | 50,166 (0%) | 0% | 115.7 | 1,160,517 | Common Stock |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.94 per share. | 04 Nov 2022 | 18,293 | 58,426 (0%) | 0% | 131.9 | 2,413,578 | Common Stock |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2022 | 16,953 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Thibaut Mongon | Exec VP, WW Chair, Consumer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2022 | 18,293 | 0 | - | - | Employee Stock Options (Right to Buy) |